Our data suggest that the robust cancer-specific hypermethylation in the promoter regions of CD133, CD147, and CD24 by bisulfite genomic sequencing analysis is in direct agreement with our MSP results in OSCC cell lines (Figure 3). The gene discussed is CD24; the disease is cancer.